<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Noelia Rodriguez Mier</style></author><author><style face="normal" font="default" size="100%">Vermeulen, François</style></author><author><style face="normal" font="default" size="100%">Géraldine Daneau</style></author><author><style face="normal" font="default" size="100%">Simeon Wanyama</style></author><author><style face="normal" font="default" size="100%">Proesmans, Marijke</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical Evolution and Disease Burden in Belgian Cystic Fibrosis Patients: effect of Newborn Screening?</style></title><secondary-title><style face="normal" font="default" size="100%">Belgian Journal of Paediatrics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023-01-18</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">297</style></number><volume><style face="normal" font="default" size="100%">23</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Objectives:&amp;nbsp;We compared the clinical evolution and disease burden of 3 groups of Belgian children with cystic fibrosis (CF) depending on the mode of diagnosis: meconium ileus (MI), newborn screening (NBS) and clinical diagnosis (non-NBS) at 1-, 2- and 6 years of age.Methods:&amp;nbsp;We conducted a retrospective observational cohort study based on data collected from the Belgian CF Registry report of 2016 including patients diagnosed between January 2006 and December 2016.&lt;/p&gt;

&lt;p&gt;Results:&amp;nbsp;306 CF patients were enrolled. Age at diagnosis was the lowest in MI patients (median 0.12 months, IQR 0.00-0.36 months) but lower in NBS patients (median 1.38 months, IQR 0.82-1.74 months) compared to non-NBS patients (8.01 months, IQR 2.47-37.58 months, p-value &amp;lt; 0.001). Height z-scores at 1 year of age were better in NBS patients (median = -0.13, IQR -0.99 – 0.50) compared to non-NBS patients (MI median = -0.56, IQR = -01.53 – 0.02, non-NBS median = -0.54, IQR = -1.02 – 0.12, p = 0.03377). Annual prevalence of bacterial infections was not different between the 3 patient groups at the predefined time points.&amp;nbsp;Burden of therapy was lower for NBS during the first 2 years of life. Lung function at 6 years of age did not show significant differences between the 3 groups.&lt;/p&gt;

&lt;p&gt;Conclusion:&amp;nbsp;This study suggests a beneficial trend for NBS as primary method of CF detection when comparing age at diagnosis, clinical evolution and burden of therapy between NBS and clinically diagnosed CF patients. A standardized care program after CF-NBS is needed.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><section><style face="normal" font="default" size="100%">292</style></section></record></records></xml>